STOCK TITAN

[Form 4] Roivant Sciences Ltd. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) reported insider activity by a director. On 10/20/2025, the director received 1,507 common shares under the Non-Employee Director Compensation Plan, which were fully vested on the grant date.

To cover tax withholding, the issuer executed a net settlement, withholding 281 shares at $17.74. After these transactions, the director directly owns 118,388 shares.

Roivant Sciences Ltd. (ROIV) ha riferito attività da insider da parte di un membro del consiglio. Il 20/10/2025, il direttore ha ricevuto 1.507 azioni ordinarie nell'ambito del Non-Employee Director Compensation Plan, che sono state acquisite integralmente al momento dell'assegnazione.

Per coprire le ritenute fiscali, l'emittente ha eseguito un regolamento netto, trattenendo 281 azioni a $17,74. Dopo queste transazioni, il direttore possiede direttamente 118.388 azioni.

Roivant Sciences Ltd. (ROIV) informó actividad de insider por parte de un director. El 20/10/2025, el director recibió 1.507 acciones comunes bajo el Non-Employee Director Compensation Plan, las cuales quedaron totalmente adquiridas en la fecha de concesión.

Para cubrir la retención de impuestos, el emisor ejecutó una liquidación neta, reteniendo 281 acciones a $17,74. Después de estas transacciones, el director posee directamente 118.388 acciones.

Roivant Sciences Ltd. (ROIV) 이사에 의한 내부자 거래가 보고되었습니다. 2025년 10월 20일에 이사는 Non-Employee Director Compensation Plan에 따라 1,507주의 보통주를 받았고, 이는 수여일에 전액 취득되었습니다.

세금 원천징수를 보전하기 위해 발행사는 순결제(net settlement)를 실행하여 281주를 $17.74로 원천징수했습니다. 이 거래 후 이사는 직접 118,388주를 보유합니다.

Roivant Sciences Ltd. (ROIV) a annoncé une activité d'initié de la part d'un administrateur. Le 20/10/2025, l'administrateur a reçu 1 507 actions ordinaires dans le cadre du Non-Employee Director Compensation Plan, qui ont été entièrement acquises à la date d'octroi.

Pour couvrir les retenues d'impôt, l'émetteur a procédé à une règlement net, retenant 281 actions à 17,74 dollars. Après ces transactions, l'administrateur détient directement 118 388 actions.

Roivant Sciences Ltd. (ROIV) meldete Insider-Aktivitäten eines Direktors. Am 20.10.2025 erhielt der Direktor 1.507 Stammaktien im Rahmen des Non-Employee Director Compensation Plan, die am Zuteilungsdatum vollständig erworben waren.

Um die Steuerabzüge zu decken, führte der Emittent eine Net Settlement durch und behielt 281 Aktien zu 17,74 USD ein. Nach diesen Transaktionen besitzt der Direktor direkt 118.388 Aktien.

Roivant Sciences Ltd. (ROIV) أبلغت عن نشاط داخلي من قبل مدير. في 20/10/2025، تلقى المدير 1,507 أسهم عادية بموجب خطة تعويض المديرين غير العاملين، والتي تم اقتناءها بالكامل في تاريخ المنح.

ولتغطية خصم الضرائب، نفّذ المصدر التسوية الصافية، مع حجز 281 سهماً بسعر 17.74 دولاراً. بعد هذه المعاملات، يملك المدير مباشرة 118,388 سهماً.

Positive
  • None.
Negative
  • None.

Roivant Sciences Ltd. (ROIV) ha riferito attività da insider da parte di un membro del consiglio. Il 20/10/2025, il direttore ha ricevuto 1.507 azioni ordinarie nell'ambito del Non-Employee Director Compensation Plan, che sono state acquisite integralmente al momento dell'assegnazione.

Per coprire le ritenute fiscali, l'emittente ha eseguito un regolamento netto, trattenendo 281 azioni a $17,74. Dopo queste transazioni, il direttore possiede direttamente 118.388 azioni.

Roivant Sciences Ltd. (ROIV) informó actividad de insider por parte de un director. El 20/10/2025, el director recibió 1.507 acciones comunes bajo el Non-Employee Director Compensation Plan, las cuales quedaron totalmente adquiridas en la fecha de concesión.

Para cubrir la retención de impuestos, el emisor ejecutó una liquidación neta, reteniendo 281 acciones a $17,74. Después de estas transacciones, el director posee directamente 118.388 acciones.

Roivant Sciences Ltd. (ROIV) 이사에 의한 내부자 거래가 보고되었습니다. 2025년 10월 20일에 이사는 Non-Employee Director Compensation Plan에 따라 1,507주의 보통주를 받았고, 이는 수여일에 전액 취득되었습니다.

세금 원천징수를 보전하기 위해 발행사는 순결제(net settlement)를 실행하여 281주를 $17.74로 원천징수했습니다. 이 거래 후 이사는 직접 118,388주를 보유합니다.

Roivant Sciences Ltd. (ROIV) a annoncé une activité d'initié de la part d'un administrateur. Le 20/10/2025, l'administrateur a reçu 1 507 actions ordinaires dans le cadre du Non-Employee Director Compensation Plan, qui ont été entièrement acquises à la date d'octroi.

Pour couvrir les retenues d'impôt, l'émetteur a procédé à une règlement net, retenant 281 actions à 17,74 dollars. Après ces transactions, l'administrateur détient directement 118 388 actions.

Roivant Sciences Ltd. (ROIV) meldete Insider-Aktivitäten eines Direktors. Am 20.10.2025 erhielt der Direktor 1.507 Stammaktien im Rahmen des Non-Employee Director Compensation Plan, die am Zuteilungsdatum vollständig erworben waren.

Um die Steuerabzüge zu decken, führte der Emittent eine Net Settlement durch und behielt 281 Aktien zu 17,74 USD ein. Nach diesen Transaktionen besitzt der Direktor direkt 118.388 Aktien.

Roivant Sciences Ltd. (ROIV) أبلغت عن نشاط داخلي من قبل مدير. في 20/10/2025، تلقى المدير 1,507 أسهم عادية بموجب خطة تعويض المديرين غير العاملين، والتي تم اقتناءها بالكامل في تاريخ المنح.

ولتغطية خصم الضرائب، نفّذ المصدر التسوية الصافية، مع حجز 281 سهماً بسعر 17.74 دولاراً. بعد هذه المعاملات، يملك المدير مباشرة 118,388 سهماً.

Roivant Sciences Ltd. (ROIV) 报告了一位董事的内幕活动。于2025年10月20日,该董事在 Non-Employee Director Compensation Plan 下获得 1,507 股普通股,这些股票在授予日已全部归属。

为覆盖税费代扣,发行方执行了 净清算,扣留 281 股,价格为 $17.74。经这些交易后,该董事直接持有 118,388 股

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Oren Ilan

(Last) (First) (Middle)
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY

(Street)
LONDON X0 SW1H 0DB

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 10/20/2025 A 1,507(1) A $0(1) 118,669 D
Common Shares 10/20/2025 F 281(2) D $17.74 118,388 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.
2. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.
By: /s/ Jo Chen, as Attorney-in-Fact for Ilan Oren 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Roivant Sciences

NASDAQ:ROIV

ROIV Rankings

ROIV Latest News

ROIV Latest SEC Filings

ROIV Stock Data

12.37B
425.86M
26.13%
76.8%
5.72%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
LONDON